A photo of Benjamin Mizukawa.

Benjamin E. Mizukawa, MD


  • Research Director, Pediatric Cancer Avatar Program
  • Assistant Professor, UC Department of Pediatrics

About

Insurance Information

Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.

View Insurance Information

Publications

Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. Hegde, S; Gasilina, A; Wunderlich, M; Lin, Y; Buchholzer, M; Krumbach, OH F; Akbarzadeh, M; Ahmadian, MR; Seibel, W; Zheng, Y; et al. Leukemia. 2022; 36:637-647.

Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. Sabnis, HS; Shulman, DS; Mizukawa, B; Bouvier, N; Zehir, A; Fangusaro, J; Fabrizio, VA; Whitlow, C; Winchester, M; Agresta, L; et al. Journal of Clinical Oncology. 2021; 39:3822-3828.

Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. Rubinstein, JD; Shah, R; Breese, EH; Burns, KC; Mangino, JL; Norris, RE; Lee, L; Mizukawa, B; O'Brien, MM; Phillips, CL; et al. Pediatric Blood and Cancer. 2021; 68.

Hyperdiploid Precursor B-acute Lymphoblastic Leukemia Presenting as a Cavernous Sinus Mass in a 4-Year-old Male. Sabulski, A; Bartlett, AL; Koch, BL; Vatner, R; Mizukawa, B; Phillips, CL. Journal of Pediatric Hematology/Oncology. 2021; 43:e494-e497.

Hyperdiploid Precursor B-acute Lymphoblastic Leukemia Presenting as a Cavernous Sinus Mass in a 4-Year-old Male. Sabulski, A; Bartlett, AL; Koch, BL; Vatner, R; Mizukawa, B; Phillips, CL. Journal of Pediatric Hematology/Oncology. 2021; 43:e494-e497.

PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. Wunderlich, M; Manning, N; Sexton, C; O’Brien, E; Byerly, L; Stillwell, C; Perentesis, JP; Mulloy, JC; Mizukawa, B. Frontiers in Oncology. 2021; 11.

FOXM1 regulates leukemia stem cell quiescence and survival in MLL-rearranged AML. Sheng, Y; Yu, C; Liu, Y; Hu, C; Ma, R; Lu, X; Ji, P; Chen, J; Mizukawa, B; Huang, Y; et al. Nature Communications. 2020; 11.

Cyclosporine enhances the sensitivity to lenalidomide in MDS/AML in vitro. He, X; Dou, A; Feng, S; Roman-Rivera, A; Hawkins, C; Lawley, L; Zhang, J; Wunderlich, M; Mizukawa, B; Halene, S; et al. Experimental Hematology. 2020; 86:21-27.e2.

Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML. Jones, LM; O'Brien, MM; Breese, EH; Absalon, M; Burns, KC; Grimley, M; Mizukawa, B; Lee, LH; Perentesis, JP; Phillips, CL. Journal of Clinical Oncology. 2020; 38:e22502-e22502.

Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. Hayashi, Y; Goyama, S; Liu, X; Tamura, M; Asada, S; Tanaka, Y; Fukuyama, T; Wunderlich, M; O'Brien, E; Mizukawa, B; et al. Nature Communications. 2019; 10.

Patient Ratings and Comments

All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey